Navafenterol, a new drug for the treatment of chronic obstructive airway disease
10.12092/j.issn.1009-2501.2024.04.006
- Author:
Yuru LIU
1
;
Wenwen WU
1
;
Gang WANG
1
;
Yuru LIU
2
;
Wenwen WU
2
;
Gang WANG
2
Author Information
1. Department of Respiratory and Critical Care Medicine, Clinical Research Center for Respiratory Disease, West China Hospital, Sichuan University
2. State Key Laboratory of Respiratory Health and Multimorbidity
- Publication Type:Journal Article
- Keywords:
asthma;
bronchodilator;
chronic obstructive pulmonary disease;
muscarinic receptor antagonist;
navafenterol;
β2 receptor agonist
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2024;29(4):401-405
- CountryChina
- Language:Chinese
-
Abstract:
Navafenterol is a new compound with both muscarinic receptor antagonist and β2 receptor agonist effects in a single molecule, who is being developed for the treatment of chronic obstructive airway disease such as chronic obstructive pulmonary disease and asthma. These pilot clinical studies found that it can significantly improve lung function and symptoms, and is safe and well tolerated. Common treatment emergent adverse events include headache, nasopharyngitis, and dizziness. It may become a next-generation bronchodilator for chronic obstructive airway disease. This review introduced the prospective of Navafenterol.
